We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





LumiraDx Demonstrates Fast, High Performance, Portable POC Diagnostic Solution

By LabMedica International staff writers
Posted on 24 May 2023

LumiraDx (London, UK) is presenting its innovative diagnostic solutions at this year's WorldLab-EuroMedLab in Rome, Italy, 21-25 May, including its LumiraDx Platform which is designed to perform multiple tests on one single instrument wherever needed. More...

The LumiraDx Platform is similar to a portable laboratory, compact yet capable of delivering lab-grade results in a variety of care settings, thereby bringing clinical decision-making closer to the patient. This rapid, high-performing, portable point-of-care (POC) diagnostic solution employs active microfluidic technology, providing results for a range of analytes, including NT-proBNP, HbA1c, and CRP, within minutes. The single, portable instrument offers a simple and uniform workflow for all tests and is user-friendly - all that's needed is to follow the on-screen video instructions for high-sensitivity results in minutes.

The LumiraDx Platform serves as a cost-effective replacement for multiple POC systems. Its compact, lightweight design, combined with actively controlled microfluidic test strips and secure connectivity, yields lab-grade results in a matter of minutes. Both the device and test strip employ several analytical electronic quality control measures to ensure the test's integrity and validity, with automated functionality checks and test strip performance controls being conducted throughout the test's operational stages. Regardless of whether healthcare professionals are using direct fingerstick or swab methods, the LumiraDx Platform's 'easy to use' test workflow employs 'easy to retrieve' small sampling directly at the patient's side.

With a pipeline of over 30 assays, LumiraDx's POCT menu is primarily focused on some of the most commonly diagnosed or managed conditions, including coagulation disorders, infectious disease, cardiovascular conditions, and diabetes. By integrating multiple technologies and sample types into one device, the LumiraDx Platform facilitates the continued expansion of a comprehensive test menu for conditions diagnosed and managed in community-based healthcare settings.

Related Links:
LumiraDx 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Latex Test
SLE-Latex Test
New
Calprotectin Assay
Fecal Calprotectin ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.